BM
ATRA icon

Bridger Management’s Atara Biotherapeutics ATRA Stock Holding History

Bridger Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,660
Closed -$9.72M – 53
2021
Q4 		$9.72M Sell
24,660
-12,404
-33% -$5.22M 1.26% 28
2021
Q3 		$16.6M Sell
37,064
-15,944
-30% -$5.71M 1.94% 20
2021
Q2 		$20.6M Sell
53,008
-13,778
-21% -$4.91M 1.92% 19
2021
Q1 		$24M Buy
66,786
+5,796
+10% +$2.56M 2.24% 21
2020
Q4 		$29.9M Sell
60,990
-2,304
-4% -$1.06M 2.28% 20
2020
Q3 		$20.5M Sell
63,294
-8,137
-11% -$2.77M 1.64% 24
2020
Q2 		$26M Sell
71,431
-18,425
-21% -$4.65M 2.41% 19
2020
Q1 		$19.1M Sell
89,856
-27,459
-23% -$8.72M 2.21% 20
2019
Q4 		$48.3M Buy
117,315
+10,874
+10% +$3.75M 3.48% 11
2019
Q3 		$37.6M Buy
106,441
+37,655
+55% +$14M 3.1% 16
2019
Q2 		$34.6M Sell
68,786
-1,322
-2% -$933K 2.71% 20
2019
Q1 		$69.7M Sell
70,108
-18,169
-21% -$16.9M 5.51% 4
2018
Q4 		$76.7M Sell
88,277
-10,093
-10% -$9.37M 6.39% 1
2018
Q3 		$102M Hold
98,370
– – 5.88% 2
2018
Q2 		$90.4M Sell
98,370
-3,199
-3% -$3.44M 4.9% 4
2018
Q1 		$99M Sell
101,569
-2,375
-2% -$2.16M 6.01% 2
2017
Q4 		$47M Buy
103,944
+37,843
+57% +$14M 3.1% 16
2017
Q3 		$27.3M Buy
66,101
+5,133
+8% +$1.93M 1.64% 28
2017
Q2 		$21.3M Buy
60,968
+4,612
+8% +$1.78M 1.22% 34
2017
Q1 		$29M Buy
56,356
+24,423
+76% +$10.1M 1.65% 31
2016
Q4 		$11.3M Sell
31,933
-7,910
-20% -$3.35M 0.79% 33
2016
Q3 		$21.3M Sell
39,843
-796
-2% -$432K 1.44% 29
2016
Q2 		$22.9M Buy
40,639
+11,061
+37% +$5.31M 1.48% 27
2016
Q1 		$14.1M Buy
29,578
+1,304
+5% +$587K 0.97% 31
2015
Q4 		$18.7M Sell
28,274
-1,103
-4% -$834K 0.62% 28
2015
Q3 		$23.1M Buy
29,377
+9,325
+47% +$11.4M 1.57% 24
2015
Q2 		$26.4M Buy
20,052
+1,059
+6% +$1.21M 0.84% 33
2015
Q1 		$19.7M Buy
18,993
+9,255
+95% +$6.12M 1.32% 29
2014
Q4 		$6.51M Buy
+9,738
New +$5.95M 0.41% 38

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bridger Management's ATRA Position: Q1 2022 in Review

Bridger Management sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 24,660 shares — an estimated $9.72M sold.

Bridger Management first reported a position in ATRA in Q4 2014 and held it in 29 quarters. The position peaked at $102M in Q3 2018. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Bridger Management reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Bridger Management sold 24,660 Atara Biotherapeutics shares in Q1 2022, an estimated $9.72M.
  • Bridger Management first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 29 quarters.
  • Bridger Management's Atara Biotherapeutics position peaked at $102M in Q3 2018.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Bridger Management's 13F filing for Q1 2022, filed 13 May 2022.